You just read:

Entest BioMedical's Subsidiary, Zander Therapeutics, Inc., Initiates Ex Vivo Studies on Modulating NR2F6 in Canines

News provided by

Entest BioMedical Inc.

Apr 19, 2017, 08:00 ET